Due to the increased levels of COX-2 and prostaglandins in cutaneous malignancies, pharmacological intervention with COX-2 inhibitors for skin cancer has been examined in clinical trials and systematic reviews. This evidence concerns the gene PTGS2 and skin neoplasm.